New tools can propel research in lysosomal storage diseases

被引:0
|
作者
Hertz, Ellen [1 ]
Glasstetter, Logan M. [1 ]
Chen, Yu [1 ]
Sidransky, Ellen [1 ,2 ]
机构
[1] Natl Human Genome Res Inst, NIH, Med Genet Branch, Mol Neurogenet Sect, Bethesda, MD 20894 USA
[2] Natl Human Genome Res Inst, NIH, Med Genet Branch, Bld 35A Room 1E623, 35A Convent Dr, Bethesda, MD 20892 USA
关键词
Lysosomal storage diseases; Lysosome; Induced pluripotent stem cells (iPSC); CRISPR; Lyso-IP; CLN3; REVEALS; MTORC1;
D O I
10.1016/j.ymgme.2023.107729
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Historically, the clinical manifestations of lysosomal storage diseases offered an early glimpse into the essential digestive functions of the lysosome. However, it was only recently that the more subtle role of this organelle in the dynamic regulation of multiple cellular processes was appreciated. With the need for precise interrogation of lysosomal interplay in health and disease comes the demand for more sophisticated functional tools. This demand has recently been met with 1) induced pluripotent stem cell-derived models that recapitulate the disease phenotype in vitro, 2) methods for lysosome affinity purification coupled with downstream omics analysis that provide a high-resolution snapshot of lysosomal alterations, and 3) gene editing and CRISPR/Cas9-based functional genomic strategies that enable screening for genetic modifiers of the disease phenotype. These emerging methods have garnered much interest in the field of neurodegeneration, and their use in the field of metabolic disorders is now also steadily gaining momentum. Looking forward, these robust tools should accelerate basic science efforts to understand lysosomal dysfunction distal to substrate accumulation and provide translational opportunities to identify disease-modifying therapies.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] What can cell biology tell us about heterogeneity in lysosomal storage diseases?
    Gieselmann, V
    ACTA PAEDIATRICA, 2005, 94 : 80 - 86
  • [22] Rheumatologic Manifestations of Lysosomal Storage Diseases
    Shiari, Reza
    Parvaneh, Vadood Javadi
    IRANIAN JOURNAL OF CHILD NEUROLOGY, 2012, 6 (04) : 20 - 20
  • [23] From Lysosomal Storage Diseases to NKT Cell Activation and Back
    Pereira, Catia S.
    Ribeiro, Helena
    Macedo, M. Fatima
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (03):
  • [24] Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities
    Maegawa, Gustavo H. B.
    JOURNAL OF CHILD NEUROLOGY, 2019, 34 (06) : 339 - 358
  • [25] Substrate reduction therapy for lysosomal storage diseases
    Cox, TM
    ACTA PAEDIATRICA, 2005, 94 : 69 - 75
  • [26] Diagnosis of lysosomal storage diseases with fetal presentation
    Bouvier, R
    Maire, I
    ANNALES DE PATHOLOGIE, 1997, 17 (04) : 277 - 280
  • [27] Therapy of lysosomal storage diseases: update and perspectives
    Alejandro Lara-Aguilar, Ricardo
    Ibet Juarez-Vazquez, Clara
    Medina-Lozano, Claudina
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2011, 63 (06): : 651 - 658
  • [28] Lysosomal Storage Diseases: Heterogeneous Group of Disorders
    Wenger, David A.
    Luzi, Paola
    Rafi, Mohammad A.
    BIOIMPACTS, 2013, 3 (04) : 145 - 147
  • [29] The rapidly evolving view of lysosomal storage diseases
    Parenti, Giancarlo
    Medina, Diego L.
    Ballabio, Andrea
    EMBO MOLECULAR MEDICINE, 2021, 13 (02)
  • [30] Subcellular Nanorheology Reveals Lysosomal Viscosity as a Reporter for Lysosomal Storage Diseases
    Devany, John
    Chakraborty, Kasturi
    Krishnan, Yamuna
    NANO LETTERS, 2018, 18 (02) : 1351 - 1359